Gil Yosipovitch MD, FAADProfessor and Stiefel Chair of Medical Dermatology; Director, Miami Itch Center, Dr. Phillip Frost Department of Dermatology, Miller School of Medicine, Miami, Florida
Gil Yosipovitch, MD FAAD is a tenured Professor of Dermatology at the Miller School of Medicine at University of Miami, and Director of the Miami Itch Center, which focuses on chronic itch as a disease state. He has published more than 350 articles in books and peer reviewed journals and has edited 3 books. He is the founder and past president of the International Forum for the Study of Itch and the Chairman of the Scientific Board of the National Eczema Association. He serves on the editorial boards of 6 key specialty journals. In addition, he received one of the highest awards in dermatology, the Marion B. Sulzberger lectureship award, at the 2016 AAD meeting for his work on itch.
Dr. Yosipovitch was awarded several other prestigious awards for his research including the Heinz Maurer prize by the German Dermatology Society in 1998 and the inaugural Jeff Bernhard award in the World Conference of Itch in Boston in 2013 and the highest medical award by the Wroclaw Medical University in October 2017 for his work on itch. During his 11 years of tenure at Wake Forest School of Medicine, he received the Clinical Investigator Award and the Friends of Students’ Award for Teacher of the Year. Dr. Yosipovitch has given more than 400 invited lectures to dermatology groups and organizations around the world and has mentored more than 30 fellows, PhD students and post-Doc fellows.
Recent Contributions to PracticeUpdate:
- Longitudinal Course of Sleep Disturbance and Relationship With Itch in Adult Patients With Atopic Dermatitis
- Introduction of a Specific Dermatological Rehabilitation Programme for Patients With Chronic Pruritus
- A Consensus Statement on Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice
- Efficacy of Dupilumab in Chronic Prurigo and Chronic Idiopathic Pruritus
- Sleep Disturbance in Adult Dermatological Patients
- Nemolizumab and Topical Agents for Atopic Dermatitis With Pruritus
- Cannabinoids for the Treatment of Chronic Pruritus
- Itch and Mental Health in Dermatological Patients
- Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria
- Humanistic Burden of Chronic Pruritus in Patients With Inflammatory Dermatoses